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1. Introduction 
Thrombotic microangiopathy (TMA) is a significant complication following hematopoietic 
stem-cell transplantation (HSCT), which is also described as transplant-associated 
microangiopathy (TAM). Endothelial injuries from multiple factors contribute to the 
formation of widespread platelet thrombi within the microvasculature, causing hemolytic 
anemia and damage to various organs(Daly et al, 2002a; Daly et al, 2002b; Nishida et al, 2004; 
Pettitt & Clark, 1994; Shimoni et al, 2004; Zeigler et al, 1996; Zeigler et al, 1995). Owing to the 
difficulty in making a definitive diagnosis of TMA in HSCT recipients, it is usually 
diagnosed based on clinical and laboratory findings, such as serum lactic dehydrogenase 
(LD) levels and the percentage of fragmented erythrocytes (Martinez et al, 2005; Oran et al, 
2007; Zeigler et al, 1995). 
However, these findings are frequently nonspecific, because they are influenced by many 
other clinical events. Some research group has been reported case series involving TMA 
with steroid-refractory diarrhea. They showed that TMA frequently involves the 
gastrointestinal tract in HSCT recipients (Inamoto et al, 2009; Narimatsu et al, 2005; Nishida 
et al, 2004). 
The transplantation-related TMA has different clinical features and outcomes from TMA in 
the patients with other situations. In this chapter, I describe clinical feature and treatment of 
the transplantation-related TMA. 
2. Classic and intestinal TMA – Clinical manifestations 
The most common criteria for classic TMA diagnosis following HSCT are the signs of 
microangiopathic hemolysis (Martinez et al, 2005; Oran et al, 2007). On the other hand, in the 
patients with intestinal TMA, red cell fragmentation and serum LD elevation were usually 
mild or absent, and serum haptoglobin levels were detectable(Inamoto et al, 2009; Narimatsu 
et al, 2005; Nishida et al, 2004). Postmortem studies failed to find any evidence of TMA other 
than in the intestine(Narimatsu et al, 2005). Neither renal dysfunction nor neurologic 
abnormalities were not usually present in those patients. Based on the conventional pentad 
of HUS/TTP, TMA was not diagnosed in any of them in intestinal TMA. These findings 
suggest a difference in pathogenesis between intestinal TMA(Inamoto et al, 2009; Narimatsu 
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et al, 2005; Nishida et al, 2004) following HSCT and either classic TTP (Furlan et al, 1998) or 
classic TMA following HSCT(Allford et al, 2002; Nishida et al, 2004).  
The differences in the observations between classic TMA and intestinal TMA can be 
explained by several reasons, such as the conditioning agents and patients’ backgrounds. It 
may be also explained by following reasons. Clinicians and pathologists might not be 
commonly aware of TMA and could possibly have misinterpreted it as GVHD or infectious 
colitis. A pathological diagnosis of TMA can be difficult to make.  Thrombolysis, which 
might occur after death, might have masked the pathological findings of TMA at autopsy 
(Iwata et al, 2001). However, those explanations failed to explain this reason. Thus, further 
investigation can allow a proper interpretation of the various published reports. 
3. Diagnosis of intestinal TMA 
Total colonoscopy from the rectum to the terminal ileum with biopsy is required for the 
diagnosis of intestinal TMA. The patients had focal TMA lesions of various distributions. 
Thus, biopsy of the rectum alone might have missed the diagnosis of TMA. Colonoscopic 
findings of TMA were diverse (Narimatsu et al, 2005). It was difficult to differentiate TMA 
from intestinal GVHD (Iqbal et al, 2000; Martin et al, 2004) and CMV colitis.(Meyers et al, 
1986) Furthermore, TMA was complicated with GVHD and CMV colitis in many patients 
(Inamoto et al, 2009; Narimatsu et al, 2005). Macroscopic observation alone is not sufficient to 
make a diagnosis of TMA. Laboratory findings alone are also not useful in previous studies 
(Inamoto et al, 2009; Narimatsu et al, 2005; Nishida et al, 2004). Clinically available risk 
factors were also not identified in previous studies; laboratory data such as LD at the time of 
colonoscopy were not significantly different between patients with and without TMA. Thus, 
a biopsy and a pathological examination extending from the rectum to the terminal ileum 
are probably necessary to make a definite diagnosis in patients with diarrhea. 
4. Pathological features 
Suggested mechanisms on onset of intestinal TMA was shown in Figure 1; there is limited 
information on the pathogenesis of intestinal TMA(Inamoto et al, 2009; Narimatsu et al, 2005; 
Nishida et al, 2004).  Classic TMA after myeloablative HSCT has a multifactorial etiology 
that includes immunosuppressive agents,(Pham et al, 2000; Trimarchi et al, 1999) total body 
irradiation (TBI) (Ballermann, 1998), CMV infection (Takatsuka et al, 2003), and acute GVHD 
(Ertault-Daneshpouy et al, 2004). These factors injure the vascular endothelium of many 
organs (Pettitt & Clark, 1994). In contrast, particular factors specifically affecting the 
gastrointestinal system are largely involved in the etiology of intestinal TMA after HSCT.  It 
should be noted that most patients with intestinal TMA had overlapping gastrointestinal 
GVHD and/or CMV colitis(Narimatsu et al, 2005).  An animal study has demonstrated that 
the vascular endothelium is a target of alloimmunity (Ertault-Daneshpouy et al, 2004). The 
previous report by us supports this hypothesis(Narimatsu et al, 2005). GVHD was associated 
with gastrointestinal TMA, and the association could partly explain why TMA was located 
in the gut.  It is reasonable to assume that GVHD damages the gastrointestinal endothelium, 
leading to the development of intestinal TMA. Regimen-related toxicity (RRT) of the gut is 
known to increase the risk of intestinal GVHD.(Goldberg et al, 2005) Gastrointestinal damage 
due to preparative regimens might contribute to the development of intestinal TMA. In our 
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previous study, CMV infection, which is another putative etiology of TMA,(Takatsuka et al, 
2003) was documented in 4 patients, and all were located in the gut. (Narimatsu et al, 2005) 
CMV colitis might be associated with intestinal TMA following HSCT. 
 
Fig. 1. Suggested mechanisms on onset of intestinal TMA 
Inamoto et al presented the usefulness of Immunostainings(Inamoto et al, 2009). They made 
histopathological diagnosis of “intestinal TAM” by the presence of microangiopathy with 
ischemic (noninflammatory) crypt loss. Microangiopathy was confirmed by hematoxylin–
eosin staining and CD34 immunostaining. The clues for endothelial injury are swollen 
endothelial cells and denuded endothelial cells. Ischemic changes followed by 
microangiopathy included individual non-inflammatory crypt degeneration with 
detachment and apoptosis of epithelial cells, wedge-shaped segmental injury and interstitial 
edema with hemorrhage or fragmented RBCs. Although, pathological definition of intestinal 
TMA is uncertain, these pathological findings are worth investigating. 
5. Treatment 
While the appropriate treatment of intestinal TMA is unknown, a published series of cases 
suggests that reducing the dose of immunosuppressants may be effective for intestinal TMA 
as well as classic TMA.(Inamoto et al, 2009; Nishida et al, 2004) On the other hand, our study 
group suggested that patients with intestinal GVHD and TMA could be improved without 
immunosuppressant reduction. This observation would indicate that the management of 
GVHD, rather than immunosuppressant reduction, is important in the treatment of 
intestinal TMA. In fact, the reduction of immunosuppressants to prevent vascular 
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endothelial damage would aggravate GVHD, and increase the risk of TMA progression. 
(Narimatsu et al, 2005) Considering these possibilities, one should be vigilant when deciding 
on the dose of immunosuppressant for TMA after HSCT.   
The treatments used for classic TTP, such as fresh frozen plasma and plasma exchange, have 
been tried for TMA after bone marrow transplantation.(Allford et al, 2002) However, the 
efficacy of these treatments in patients with intestinal TMA remains unclear. Minimizing the 
damage to the intestinal mucosa and the vascular endothelium would be more desirable for 
the management of intestinal TMA than the treatments designed for classic TTP. 
6. Conclusion and future direction 
The intestinal TMA is a significant complication after HSCT. When transplant recipients 
develop refractory diarrhea, Intestinal TMA needs to be included in the differential 
diagnoses. However, conventional diagnostic criteria can overlook TMA. Thus, the 
diagnosis of intestinal TMA after HSCT requires endoscopy with biopsy.   
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